{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:05:02Z","timestamp":1781503502796,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.schres.2020.11.025","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:14:02Z","timestamp":1605809642000},"page":"590-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders"],"prefix":"10.1016","volume":"228","author":[{"given":"Robert L.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Tveito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Kylles\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin M.","family":"Jukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2020.11.025_bb0005","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5498\/wjp.v4.i2.30","article-title":"What\u2019s in a name? Compliance, adherence and concordance in chronic psychiatric disorders","volume":"4","author":"Chakrabarti","year":"2014","journal-title":"World J Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/ps.49.2.196","article-title":"Compliance with medication regimens for mental and physical disorders","volume":"49","author":"Cramer","year":"1998","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2020.11.025_bb0020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/schbul\/sbs097","article-title":"Guideline-concordant antipsychotic use and mortality in schizophrenia","volume":"39","author":"Cullen","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.11.025_bb0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.psychres.2019.03.029","article-title":"Psychiatrists\u2019 attitude towards the use of clozapine in the treatment of refractory schizophrenia: a nationwide survey","volume":"275","author":"Daod","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.11.025_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.schres.2020.11.025_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.forsciint.2013.03.021","article-title":"Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum","volume":"229","author":"Fisher","year":"2013","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.schres.2020.11.025_bb0040","author":"Food and Drug Administration"},{"key":"10.1016\/j.schres.2020.11.025_bb0045","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1176\/appi.ajp.161.4.692","article-title":"Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia","volume":"161","author":"Gilmer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4088\/JCP.v62n0515","article-title":"Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study","volume":"62","author":"Grunebaum","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.schres.2020.11.025_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S29549","article-title":"Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions","volume":"7","author":"Hugtenburg","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.schres.2020.11.025_bb0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/JCP.0b013e3181d2191e","article-title":"Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level","volume":"30","author":"Jonsdottir","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2020.11.025_bb0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(18)33079-4","article-title":"Confronting the most challenging risk factor: non-adherence","volume":"393","author":"Kones","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2020.11.025_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2020.11.025_bb0095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.11.025_bb0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2020.11.025_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/acps.12825","article-title":"Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia","volume":"137","author":"McCutcheon","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2020.11.025_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2020.11.025_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.11.025_bb0120","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2020.11.025_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","article-title":"Impact of medication adherence on hospitalization risk and healthcare cost","volume":"43","author":"Sokol","year":"2005","journal-title":"Med. Care"},{"key":"10.1016\/j.schres.2020.11.025_bb0130","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up","volume":"44","author":"Taipale","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.11.025_bb0135","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2020.11.025_bb0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.schres.2019.11.022","article-title":"Assessment of adherence to oral antipsychotic medications: what has changed over the past decade?","volume":"215","author":"Velligan","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.11.025_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2020.11.025_bb0150","author":"World Health Organization"},{"key":"10.1016\/j.schres.2020.11.025_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.schres.2018.05.014","article-title":"Measuring adherence to antipsychotic medications for schizophrenia: concordance and validity among a community sample in rural China","volume":"201","author":"Xu","year":"2018","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642030565X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099642030565X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:46:58Z","timestamp":1760298418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099642030565X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":31,"alternative-id":["S092099642030565X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.11.025","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}